Bruker Corp. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Bruker Corp. filed its Q1 2024 10-Q, detailing financial performance and disclosures for the period ending March 31, 2024.</b>

AI Summary

BRUKER CORP (BRKRP) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Bruker Corp. filed a 10-Q report for the period ending March 31, 2024. The filing includes data related to various financial statement line items and disclosures. Specific dates mentioned include 2024-03-31, 2023-12-31, and 2023-03-31. Entities such as Tornado Spectral Systems Inc. and Biognosys Ag are referenced. The report covers periods from January 1, 2024, to March 31, 2024, and comparative periods in 2023.

Why It Matters

For investors and stakeholders tracking BRUKER CORP, this filing contains several important signals. This 10-Q filing provides an update on Bruker Corp.'s financial position and operational activities for the first quarter of 2024, which is crucial for investors to assess recent performance and trends. The detailed disclosures within the report, including references to specific entities and financial instruments, offer insights into the company's ongoing business operations and potential future developments.

Risk Assessment

Risk Level: low — BRUKER CORP shows low risk based on this filing. The filing is a standard 10-Q report, which is routine for publicly traded companies and does not inherently indicate significant new risks or positive/negative developments beyond normal business operations.

Analyst Insight

Review the detailed financial statements and disclosures in the 10-Q to understand Bruker Corp.'s Q1 2024 performance and any changes from previous periods.

Key Numbers

• 2024-03-31 — Period End Date (Conformed period of report)
• 2024-05-10 — Filing Date (Filed as of date)
• 2023-03-31 — Comparative Period End Date (Data for Q1 2023)
• 2023-12-31 — Previous Year End Date (Reference for balance sheet items)

Key Players & Entities

• BRUKER CORP (company) — Filer name
• 2024-03-31 (date) — Conformed period of report
• 2024-05-10 (date) — Filed as of date
• Tornado Spectral Systems Inc. (company) — Referenced entity
• Biognosys Ag (company) — Referenced entity
• 2023-03-31 (date) — Comparative period end date
• 2024-01-01 (date) — Period start date
• 2023-12-31 (date) — Previous year-end date

FAQ

Industry Context

Bruker Corporation operates in the scientific instruments industry, providing analytical and diagnostic tools for research and applied markets.

Regulatory Implications

As a publicly traded company, Bruker Corp. is subject to SEC regulations, including the requirement to file quarterly reports (10-Q) to disclose financial and operational information.

What Investors Should Do

1. Analyze the financial statements within the 10-Q for revenue, net income, and other key performance indicators.
2. Review the Management's Discussion and Analysis (MD&A) section for insights into the company's performance drivers and outlook.
3. Examine any new risk factors or legal proceedings disclosed in the report.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q
• 2024-05-10: Filing Date — Date the 10-Q was officially filed with the SEC

Year-Over-Year Comparison

This filing represents the quarterly update for Q1 2024, providing a snapshot of the company's financial health and operations compared to previous periods.

Key Financial Figures

• $0.01 — standing at May 8, 2024 Common Stock, $0.01 par value per share 145,335,376 share

Filing Documents

• brkr-20240331.htm (10-Q) — 2593KB
• brkr-ex31_1.htm (EX-31.1) — 15KB
• brkr-ex31_2.htm (EX-31.2) — 16KB
• brkr-ex32_1.htm (EX-32.1) — 15KB
• 0000950170-24-057736.txt (&nbsp;) — 12696KB
• brkr-20240331.xsd (EX-101.SCH) — 1716KB
• brkr-20240331_htm.xml (XML) — 2751KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3:

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 38 Item 4:

Controls and Procedures

Controls and Procedures 40 Part II OTHER INFORMATION 41 Item 1:

Legal Proceedings

Legal Proceedings 41 Item 1A:

Risk Factors

Risk Factors 41 Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 41 Item 5: Other Information 41 Item 6: Exhibits 42

Signatures

Signatures 43 2 Table of Contents

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS BRUKER CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in millions, except share and per share data) March 31, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 340.1 $ 488.3 Accounts receivable, net 475.4 492.0 Inventories 1,060.5 968.3 Other current assets 264.4 215.6 Total current assets 2,140.4 2,164.2 Property, plant and equipment, net 586.1 599.7 Goodwill 751.9 582.6 Intangible assets, net 449.2 330.5 Operating lease assets 105.1 91.7 Deferred tax assets 280.1 297.2 Other long-term assets 193.6 184.0 Total assets $ 4,506.4 $ 4,249.9 LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY Current liabilities: Current portion of long-term debt $ 21.2 $ 121.2 Accounts payable 199.1 202.7 Deferred revenue and customer advances 485.2 400.0 Other current liabilities 477.0 478.2 Total current liabilities 1,182.5 1,202.1 Long-term debt 1,357.3 1,160.3 Long-term deferred revenue and customer advances 105.6 91.5 Deferred tax liabilities 81.8 67.7 Operating lease liabilities 85.7 74.8 Accrued pension 76.0 76.6 Other long-term liabilities 166.7 163.6 Total liabilities $ 3,055.6 $ 2,836.6 Commitments and contingencies (Note 16) Redeemable noncontrolling interests 17.9 18.7 Shareholders' equity: Preferred stock, $ 0.01 par value 5,000,000 shares authorized, no ne issued or outstanding — — Common stock, $ 0.01 par value 260,000,000 shares authorized, 176,113,521 and 175,943,705 shares issued and 145,334,642 and 145,164,826 shares outstanding at March 31, 2024 and December 31, 2023, respectively 1.7 1.7 Treasury stock, at cost, 30,778,879 shares at March 31, 2024, and December 31, 2023, respectively ( 1,237.2 ) ( 1,237.2 ) Additional paid-in capital

View Full Filing

View this 10-Q filing on SEC EDGAR